Homeostatic Roles of Eosinophils in Asthma
HOMEOS
Characterization of the Homeostatic Functions of Eosinophils in Asthma: An Exploratory Study
1 other identifier
interventional
100
0 countries
N/A
Brief Summary
The HOMEOS study is an exploratory, observational, and monocentric research. It focuses on characterizing the homeostatic roles of eosinophils in severe asthma. The primary objective is to identify eosinophil subpopulations among different groups of severe asthmatic patients using flow cytometry. The study aims to advance understanding of eosinophil diversity, which could guide new therapeutic approaches .
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Dec 2024
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 11, 2024
CompletedFirst Posted
Study publicly available on registry
November 6, 2024
CompletedStudy Start
First participant enrolled
December 4, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 4, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 4, 2027
November 6, 2024
October 1, 2024
2 years
October 11, 2024
November 4, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Flow cytometry based eosinophil phenotyping : Expression levels of cell markers CD62L, CD123, CD101, CD11b, CD193, CD125, Siglec-8 on blood eosinophils quantified by flow cytometry and expressed in % and MFI (mean fluorescence intensity)
Expression levels of cell markers CD62L, CD123, CD101, CD11b, CD193, CD125, Siglec-8 on blood eosinophils quantified by flow cytometry and expressed in % and MFI (mean fluorescence intensity)
at inclusion
Study Arms (5)
Severe Asthma Patients : Biologic Naïves
OTHERSevere Asthma Patients : Biologic Naïves
Severe Asthma Patients: Responders to Biologics
OTHERSevere Asthma Patients: Responders to Biologics
Severe Asthma Patients: Non Responders to Biologics
OTHERSevere Asthma Patients: Non Responders to Biologics
Mild asthmatics
OTHERMild asthmatics
Healthy Controls
OTHERHealthy Controls
Interventions
venous blood sampling
Eligibility Criteria
You may qualify if:
- Patients diagnosed with mild asthma with severe asthma (Biologic-naïve, responders to anti-eosinophil biologic therapies and resistant to anti-eosinophil biologic therapies), control subjects without asthma
- Signature of informed consent
- Affiliation with the French social security system
You may not qualify if:
- Non-eosinophilic asthma
- Coexistence of a chronic eosinophilic inflammatory condition other than asthma
- Other respiratory conditions (cystic fibrosis, COPD, allergic bronchopulmonary aspergillosis, etc.)
- Active smoking or a smoking history of more than 20 pack-years
- Pregnant women
- Legal incapacity or limited legal capacity
- Subject unlikely to cooperate with the study and/or with anticipated low cooperation as assessed by the investigator
- Subject without health insurance
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 11, 2024
First Posted
November 6, 2024
Study Start
December 4, 2024
Primary Completion (Estimated)
December 4, 2026
Study Completion (Estimated)
February 4, 2027
Last Updated
November 6, 2024
Record last verified: 2024-10